ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "Biologic agents and rheumatoid arthritis (RA)"

  • Abstract Number: 1466 • 2013 ACR/ARHP Annual Meeting

    Survival On Treatment Of The Second Line Biologic Therapy: Switch Or Swap Strategy?

    Ennio G. Favalli1, Martina Biggioggero2, Antonio Marchesoni3 and Pier Luigi Meroni2, 1Chair and Division of Rheumatology, Gaetano Pini Institute, University of Milan, Milan, Italy, Milan, Italy, 2Chair and Division of Rheumatology, Gaetano Pini Institute, University of Milan, Milan, Italy, 3UOC Day Hospital Rheumatology, Gaetano Pini Institute, Milan, Italy, Milano, Italy

    Background/Purpose: The strategy for the choice of the second biologic agent after the failure of the first TNF inhibitor is  still an unclear aspect in…
  • Abstract Number: 501 • 2013 ACR/ARHP Annual Meeting

    A Randomized Placebo-Controlled Phase 2 Study To Evaluate Efficacy, Safety and Tolerability Of Two Secukinumab Loading Dose Regimens In Subjects With Active Rheumatoid Arthritis Despite Treatment With Methotrexate

    Silvano Adami1, André Beaulieu2, Proton Rahman3, Bruno Seriolo4, Janet S. Lee5, Gerhard Krammer6, Brian Porter5, Anuradha Thulasiraman6 and Hanno B. Richards7, 1Rheumatology Department, University of Verona, Verona, Italy, 2Faculty of Medicine, Laval University, Quebec, QC, Canada, 3Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, 4Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, 5Novartis Pharma AG, East Hanover, NJ, 6Novartis Pharma AG, Basel, Switzerland, 7Clinical Immunology / Dermatology, Novartis Pharma AG, Basel, Switzerland

    A Randomized Placebo-Controlled Phase 2 Study to Evaluate Efficacy, Safety and Tolerability of Two Secukinumab Loading Dose Regimens in Subjects with Active Rheumatoid Arthritis Despite…
  • « Previous Page
  • 1
  • 2
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.